Rybelsus and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

Is there a direct interaction between Rybelsus and progesterone?

Rybelsus is oral semaglutide, a GLP-1 receptor agonist labeled to improve blood glucose in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk [1]. It is not a weight-loss label. Prometrium is oral micronized progesterone, labeled for preventing endometrial hyperplasia in postmenopausal women with a uterus who take conjugated estrogens, and for secondary amenorrhea [2].

Neither label describes an interaction between the two. The Rybelsus drug interactions section covers two things: insulin secretagogues and insulin, because of hypoglycemia risk, and other oral drugs, because delayed gastric emptying can change how they are absorbed [1]. Progesterone is not named in it.

The Prometrium label has no separate drug interactions section. Its only enzyme-level statement is an in-vitro finding that ketoconazole inhibited progesterone metabolism in human liver microsomes, which the label says suggests that ketoconazole or other CYP3A4 inhibitors may increase progesterone bioavailability, adding that the clinical relevance of the in-vitro findings is unknown [3]. Semaglutide has very low potential to inhibit or induce CYP enzymes [1].

Why the two labels point to different times of day

The Rybelsus label is specific. One tablet once daily, on an empty stomach in the morning, with up to 4 ounces of water and no other liquids; swallow whole; wait at least 30 minutes before eating, drinking beverages or taking other oral medicines; skip a missed dose [1]. The 3 mg starting dose for the first 30 days is not effective for glycemic control, and 7 mg or 14 mg follows [1].

The Prometrium label gives a single daily dose at bedtime: 200 mg for 12 days sequentially per 28-day cycle in a postmenopausal woman with a uterus who is receiving daily conjugated estrogens, or 400 mg at bedtime for 10 days for secondary amenorrhea [2]. The label says the capsules may cause transient dizziness and drowsiness and should be used with caution when driving a motor vehicle or operating machinery [2]. During initial therapy, a few women had extreme dizziness or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion or shortness of breath [3].

So the label schedules sit at different ends of the day: Rybelsus in the morning, Prometrium at bedtime [1][2].

Does semaglutide's effect on the stomach change progesterone absorption?

Semaglutide delays gastric emptying and can affect the absorption of other oral drugs. The Rybelsus label says to consider closer clinical or laboratory monitoring when it is used with oral drugs that have a narrow therapeutic index or that require clinical monitoring [1]. In a drug interaction study, levothyroxine exposure rose 33% when given with semaglutide tablets [1]. No clinically significant effect was seen on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin, and omeprazole did not change semaglutide levels [1]. Ethinyl estradiol and levonorgestrel are contraceptive steroids, not progesterone; the label reports no study with progesterone. The label also says the tablets are not recommended in patients with severe gastroparesis [1].

For its side, the Prometrium label reports peak serum progesterone concentrations within 3 hours of an oral dose, and that food increased progesterone bioavailability relative to fasting at a 200 mg dose [3].

What the Prometrium label says to watch for

The label lists six contraindications: hypersensitivity to the ingredients, with the capsules containing peanut oil and being contraindicated in patients allergic to peanuts; abnormal genital bleeding of unknown cause; known, suspected or past breast cancer; active or past deep vein thrombosis or pulmonary embolism; active or past arterial thromboembolic disease such as stroke or heart attack; and known liver dysfunction or disease [2]. It also says progesterone may cause some degree of fluid retention, and that women with cardiac or renal dysfunction warrant careful observation [2].

The current Prometrium label, revision 02/2026, carries no boxed warning; it was one of the first six menopausal hormone products whose updated labeling FDA approved on 2026-02-12 [3][4]. The Women's Health Initiative estrogen-plus-progestin data remain in its warnings and clinical studies sections, and that trial used medroxyprogesterone acetate, not micronized progesterone [3][5]. The label's endometrial trial and its co-administration study used conjugated estrogens 0.625 mg, not estradiol; in the co-administration study, total estrone and total equilin concentrations rose and circulating 17-beta estradiol fell slightly [3][2].

All of this describes Prometrium capsules. Compounded progesterone is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [6].

Do the two drugs share side effects?

Both can cause nausea and stomach upset, but the numbers come from different populations and cannot be added together.

In pooled placebo-controlled trials of semaglutide tablets, nausea occurred in 6% on placebo, 11% on 7 mg and 20% on 14 mg; abdominal pain in 4%, 10% and 11%; diarrhea in 4%, 9% and 10%; vomiting in 3%, 6% and 8%; and constipation in 2%, 6% and 5% [1]. Any gastrointestinal reaction occurred in 21%, 32% and 41%, and 1%, 4% and 8% stopped treatment for a gastrointestinal reason [1].

The Prometrium label's larger table comes from postmenopausal women taking cyclic progesterone 200 mg with conjugated estrogens 0.625 mg versus placebo, over 3 years: nausea or vomiting 8% versus 7%, dizziness 15% versus 9%, headache 31% versus 27%, abdominal bloating 12% versus 5% [3]. Because the active arm also took estrogen, none of those rates can be assigned to progesterone alone. In the smaller secondary-amenorrhea study of progesterone 400 mg daily, dizziness was 24% versus 4% on placebo and nausea 8% versus 0% [3].

Does progesterone affect blood glucose?

The Prometrium label lists increased blood glucose among reactions reported voluntarily after marketing, where frequency cannot be reliably estimated and a causal relationship is not established [2].

On the semaglutide side, the Rybelsus label's main drug interaction warning is hypoglycemia when it is combined with insulin or an insulin secretagogue such as a sulfonylurea, and it says to consider reducing the dose of the insulin or secretagogue when starting [1]. In a 52-week trial adding semaglutide tablets to insulin, glucose below 54 mg/dL occurred in 32% on placebo, 26% on 7 mg and 30% on 14 mg [1].